{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T01:25:40Z","timestamp":1783387540105,"version":"3.54.6"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"DOI":"10.7759\/cureus.51240","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T18:19:12Z","timestamp":1703787552000},"source":"Crossref","is-referenced-by-count":1,"title":["Methadone Withdrawal-Related Psychosis in a Patient With Hormone-Dependent Breast Cancer: A Case Report"],"prefix":"10.7759","author":[{"given":"Mauro","family":"Pinho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela O","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0924-2708.2006.00109.x","article-title":"Psychosis related to methadone withdrawal","volume":"18","author":"Cobo J","year":"2006","unstructured":"Cobo J, Ramos MM, Pel\u00e1ez T, Garc\u00eda G, Marsal F. Psychosis related to methadone withdrawal. Acta Neuropsychiatr. 2006, 18:50-1. 10.1111\/j.0924-2708.2006.00109.x","journal-title":"Acta Neuropsychiatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202107_26248","article-title":"Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review","volume":"25","author":"Lozano-L\u00f3pez MT","year":"2021","unstructured":"Lozano-L\u00f3pez MT, Gamonal-Limcaoco S, Casado-Espada N, et al.. Psychosis after buprenorphine, heroin, methadone, morphine, oxycodone, and tramadol withdrawal: a systematic review. Eur Rev Med Pharmacol Sci. 2021, 25:4554-62. 10.26355\/eurrev_202107_26248","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/9781119870203","article-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor DM","year":"2021","unstructured":"Taylor DM, Barnes TR, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. John Wiley & Sons, London; 2021. 10.1002\/9781119870203"},{"key":"ref4","article-title":"Methadone withdrawal psychosis","volume":"56","author":"Levinson I","year":"1995","unstructured":"Levinson I, Galynker II, Rosenthal RN. Methadone withdrawal psychosis. J Clin Psychiatry. 1995, 56:73-6.","journal-title":"J Clin Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.6.970","article-title":"Psychosis after ultrarapid opiate detoxification","volume":"158","author":"Shreeram SS","year":"2001","unstructured":"Shreeram SS, McDonald T, Dennison S. Psychosis after ultrarapid opiate detoxification. Am J Psychiatry. 2001, 158:970. 10.1176\/appi.ajp.158.6.970","journal-title":"Am J Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.adt.0000208912.77785.fd","article-title":"Methadone treatment of resistant paranoid schizophrenia with comorbidity of substance use disorder","volume":"6","author":"Sobih A","year":"2007","unstructured":"Sobih A, Moselhy HF. Methadone treatment of resistant paranoid schizophrenia with comorbidity of substance use disorder. Addict Disord Their Treat. 2007, 6:51-3. 10.1097\/01.adt.0000208912.77785.fd","journal-title":"Addict Disord Their Treat"},{"key":"ref7","article-title":"Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and\/or acute psychotic episodes","volume":"7","author":"Pacini M","year":"2005","unstructured":"Pacini M, Maremmani I. Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and\/or acute psychotic episodes. Heroin Addict Relat Clin Probl. 2005, 7:43-8.","journal-title":"Heroin Addict Relat Clin Probl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.142.9.1106","article-title":"Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia","volume":"142","author":"Brizer DA","year":"1985","unstructured":"Brizer DA, Hartman N, Sweeney J, Millman RB. Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry. 1985, 142:1106-7. 10.1176\/ajp.142.9.1106","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht S","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, et al.. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013, 382:951-62. 10.1016\/S0140-6736(13)60733-3","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(85)90179-9","article-title":"Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia","volume":"20","author":"Schmauss C","year":"1985","unstructured":"Schmauss C, Emrich HM. Dopamine and the action of opiates: a reevaluation of the dopamine hypothesis of schizophrenia. With special consideration of the role of endogenous opioids in the pathogenesis of schizophrenia. Biol Psychiatry. 1985, 20:1211-31. 10.1016\/0006-3223(85)90179-9","journal-title":"Biol Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad PM","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004, 64:2291-314. 10.2165\/00003495-200464200-00003","journal-title":"Drugs"},{"key":"ref12","article-title":"Prolactin-dependent rat mammary cancer: a model for man?","volume":"82","author":"Pearson OH","year":"1969","unstructured":"Pearson OH, Llerena O, Llerena L, Molina A, Butler T. Prolactin-dependent rat mammary cancer: a model for man?. Trans Assoc Am Physicians. 1969, 82:225-38.","journal-title":"Trans Assoc Am Physicians"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang PS","year":"2002","unstructured":"Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J. Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry. 2002, 59:1147-54. 10.1001\/archpsyc.59.12.1147","journal-title":"Arch Gen Psychiatry"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/217142-methadone-withdrawal-related-psychosis-in-a-patient-with-hormone-dependent-breast-cancer-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:11:31Z","timestamp":1707509491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/217142-methadone-withdrawal-related-psychosis-in-a-patient-with-hormone-dependent-breast-cancer-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.51240","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}